Footprint Pharma ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

   
Loading...

Bankruptcy Risk 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.5% 11.2% 12.7% 11.3% 4.6%  
Credit score (0-100)  21 24 20 23 46  
Credit rating  BB BB BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Gross profit  -300 -144 -368 -59.5 -1.3  
EBITDA  -300 -144 -368 -59.5 -1.3  
EBIT  -300 -144 -368 -59.5 -1.3  
Pre-tax profit (PTP)  2.5 -143.7 -367.6 -59.5 5.9  
Net earnings  2.5 -143.7 -367.6 -59.5 5.9  
Pre-tax profit without non-rec. items  2.5 -144 -368 -59.5 5.9  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  303 760 532 460 466  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  303 760 532 460 466  

Net Debt  -2.5 -460 -92.9 -20.9 -26.7  
 
See the entire balance sheet

Volume 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -300 -144 -368 -59.5 -1.3  
Gross profit growth  0.0% 52.1% -155.7% 83.8% 97.9%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  303 760 532 460 466  
Balance sheet change%  0.0% 151.4% -30.0% -13.5% 1.3%  
Added value  -300.0 -143.7 -367.6 -59.5 -1.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  300 0 140 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 -4.0 -5.0  

Profitability 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  19.8% -27.0% -56.9% -12.0% -0.3%  
ROI %  19.8% -27.0% -56.9% -12.0% -0.3%  
ROE %  0.8% -27.0% -56.9% -12.0% 1.3%  

Solidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Equity ratio %  100.0% 100.0% 100.0% 100.0% 100.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.8% 320.4% 25.3% 35.2% 2,111.1%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  2.5 460.5 92.9 20.9 26.7  

Capital use efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  2.5 460.5 92.9 20.9 26.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0